Try our Chrome extension
Easily add the current web-page from your browser directly into your changedetection.io tool, more great features coming soon!
Chrome Webstore
Changedetection.io needs your support!
You can help us by supporting changedetection.io on these platforms;
- Rate us at AlternativeTo.net
- Star us on GitHub
- Follow us at Twitter/X
- Check us out on LinkedIn
- And tell your friends and colleagues :)
The more popular changedetection.io is, the more time we can dedicate to adding amazing features!
Many thanks :)
changedetection.io team
- No history found for the specified link, bad link?
- Not enough saved change detection snapshots to produce a report.
- No history found for the specified link, bad link?
- No history found for the specified link, bad link?
- No history found for the specified link, bad link?
- No history found for the specified link, bad link?
- Not enough saved change detection snapshots to produce a report.
Not yet seconds ago
False
Not yet seconds ago
3 weeks ago
| Toggle navigation * About * Portfolio * Initiatives + Strategic Partnerships * Team * News * Contact Our Portfolio We build disruptive companies. Meet them. Read what our entrepeneurs are saying about ARCH. “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.” — David Schenkein, MD, Former CEO Location: Cambridge, MA Date of Founding: Arch Partners: Read More “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges. Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.” — Ryan Watts, Ph.D., CEO Location: San Francisco, CA Date of Founding: Arch Partners: Read More “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals. I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.” — Bill Rastetter, Ph.D., Former Chairman Location: Menlo Park, CA Date of Founding: Sample Date Arch Partners: Read More “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor. In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company. ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.” — Jay Flatley, former Executive Chairman Location: Santa Clara, CA Date of Founding: Sample Date Arch Partners: Read More “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment. ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.” — Hans Bishop, Former CEO Location: Seattle, WA Date of Founding: Arch Partners: Read More “ARCH has been much more of a partner than an investor. ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.” — Emily LeProust, Ph.D., CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Read More “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scangos, Ph.D., Former CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Read More “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.” — David Schenkein, MD, Former CEO Location: Cambridge, MA Date of Founding: Arch Partners: “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges. Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.” — Ryan Watts, Ph.D., CEO Location: San Francisco, CA Date of Founding: Arch Partners: “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals. I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.” — Bill Rastetter, Ph.D., Former Chairman Location: Menlo Park, CA Date of Founding: Sample Date Arch Partners: “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor. In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company. ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.” — Jay Flatley, former Executive Chairman Location: Santa Clara, CA Date of Founding: Sample Date Arch Partners: “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment. ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.” — Hans Bishop, Former CEO Location: Seattle, WA Date of Founding: Arch Partners: “ARCH has been much more of a partner than an investor. ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.” — Emily LeProust, Ph.D., CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scangos, Ph.D., Former CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Disruptive Companies from Great Science ARCH Portfolio Companies 908 Devices Point-of-need chemical and biomolecular analysis devices Boston, MA | NASDAQ: MASS Accompany Health Correcting disparities in home health care for marginalized communities. Bethesda, MD Aera Therapeutics Protein nanoparticle delivery platform to deliver genetic payloads into multiple organs for better response and fewer reactions. Cambridge, MA Agios Pharmaceuticals Gene-targeted cancer therapeutics Cambridge, MA | NASDAQ: AGIO AIRNA RNA editing technology harnessing endogenous enzymes to prevent off-target edits. Akamis Bio Systemic immune oncology therapies Abingdon, UK Aledade Accountable care organizations Bethesda, MD Alnylam Pharmaceuticals RNAi therapeutics Cambridge, MA | NASDAQ: ALNY Altos Labs Cellular resilience and rejuvenation San Diego, CA Arbor Biotechnologies Protein Discovery Platform for Therapeutics Cambridge, MA Areteia Therapeutics The first oral drug to treat eosinophilic asthma. CHAPEL HILL, NC Arsenal Biosciences Programmable cell cancer therapies South San Francisco, CA Aspen Neuroscience Regenerative medicine focused on Parkinson’s Disease San Diego, CA Autobahn Therapeutics Thyromimetics drug discovery San Diego, CA Basking Biosciences Reversible thrombolytic therapy for acute ischemic stroke Columbus, OH BE Biopharma New class of engineered B cell medicines. Cambridge, MA Beam Therapeutics CRISPR base-editing platform Cambridge, MA | NASDAQ: BEAM Bit Bio Precise reprogramming of stem cells into any desired cell type Cambridge, UK Bitterroot Bio Cardiovascular disease therapies Palo Alto, CA Boundless Bio Therapeutics based on ecDNA discoveries San Diego, CA | NASDAQ: BOLD Brii Biosciences Transforming China's public health Shanghai, China & San Francisco, CA | HKEX: 2137 Carrick Therapeutics Cancer therapeutics Boston, MA City Therapeutics Next generation siRNA medicines Cambridge, MA CStone Pharmaceuticals China-based cancer therapeutics Suzhou, China | HKEX: 2616 Curie Bio Helping biotech company founders launch successful therapeutics firms Boston, MA Cytrellis Biosystems Aesthetic medicine Woburn, MA Denali Therapeutics Neurodegenerative therapeutics San Francisco, CA | NASDAQ: DNLI Dewpoint Therapeutics Translating biomolecular condensate into therapeutics Boston, MA Dispatch Biotherapeutics Immunotherapies to reimagine cancer therapy Philadelphia, PA eGenesis Gene-editing for organ transplantation Cambridge, MA Elephas Biosciences Cancer diagnostics to accurately predict clinical outcomes and accelerate drug development Madison, WI Encoded Therapeutics Precision gene therapies South San Francisco, CA Encodia Protein Analysis Platform San Diego, CA Enumerix Precision DNA counting platform Palo Alto, CA EQRx (Acquired) Re-engineering drug development and pricing models Cambridge, MA | NASDAQ: EQRX Erasca Erasing cancer with AI drug discovery platform San Diego, CA | NASDAQ: ERAS Faraday Pharmaceuticals Ischemic trauma therapies Seattle, WA Gate Bioscience Small molecule drugs against disease-causing proteins Brisbane, CA Generate Biomedicines Multi-disciplinary platform for developing protein therapeutics Cambridge, MA Gossamer Bio Therapeutics in immunology, inflammation, and oncology San Diego, CA | NASDAQ: GOSS Grail (Acquired) Detect cancer early, when it can be cured. Menlo Park, CA hC Bioscience tRNA-based therapeutics for cancer and rare disease Boston, MA HiberCell Therapeutics to prevent cancer relapse and metastasis New York, NY Homeward Health Delivering healthcare to rural communities using a hybrid model of virtual and in-person services San Francisco, CA Hua Medicine Asia-based pharmaceutical development Shanghai, China | HKEX: 2552 Human Immunology Biosciences (Acquired) Precision immunology therapies San Francisco, CA Illumina Diagnostics screening platform Santa Clara, CA | NASDAQ: ILMN Inograft Biotherapeutics Organ and stem cell transplant immune suppression therapies Palo Alto, CA Insitro Machine learning for drug discovery South San Francisco, CA Jaguar Gene Therapy Gene therapies for severe genetic diseases Lake Forest, IL Juno Therapeutics (Acquired) Cancer immunotherapies Seattle, WA | NASDAQ: JUNO JUST Biotherapeutics (Acquired) Therapeutics development & manufacturing Seattle, WA JW Therapeutics China-based cancer therapeutics Shanghai, China | HKEX: 2126 Kardigan Curative therapies for cardiovascular disease South San Francisco, CA Karuna Therapeutics (Acquired) Therapeutics for cognitive impairment Boston, MA | NASDAQ: KRTX Kisbee Therapeutics Neurodegenerative disease therapies based on lipid biology Watertown, MA KSQ Therapeutics Matching Genomic Function to Diseases Cambridge, MA Kura Oncology Cancer therapeutics San Diego, CA | NASDAQ: KURA Kythera Biopharmaceuticals (Acquired) Aesthetic medicine Parsippany, NJ & CA | NASDAQ: KYTH LifeMine Therapeutics Biosynthetic therapeutics Cambridge, MA Lifordi Immunotherapeutics Leveraging anti-drug conjugates to develop treatments for autoimmune and inflammatory disorders Boston, MA Lightcast Discovery Microfluidic platform for complex and single cell analysis Cambridge, UK Lilac Therapeutics Small molecule therapies to treat kidney stones Richmond, CA Lyell Immunopharma Curative cell-based immunotherapeutics for cancer San Francisco, CA & Seattle, WA | NASDAQ: LYEL Magnet Biomedicine Discovery platform for molecular glues that exhibit therapeutic activity Cambridge, MA Matter Neuroscience App pairing personal experience and neuroscience to build better lives Maze Therapeutics Targeting genetic modifiers that can protect against disease San Francisco, CA | NASDAQ: MAZE Metsera Metabolic disease therapeutics Boston, MA | NASDAQ: MTSR Mirador Therapeutics Precision medicines for immunology and inflammation San Diego, CA Moleculent AB Cell-cell communication profiling platform Stockholm, Sweden Moonwalk Biosciences Precision epigenetic editing SOUTH SAN FRANCISCO, CA Mozart Therapeutics Autoimmune disease therapeutics Seattle, WA Myeloid Therapeutics Novel mRNA-immunotherapies to treat cancer Cambridge, MA National Resilience Re-engineering drug manufacturing in the U.S. and abroad La Jolla, CA nChroma Bio In vivo delivery methods for genetic medicines Cambridge, MA Neumora Therapeutics Precision medicines for brain diseases and disorders. Watertown, MA | NASDAQ: NMRA Nutcracker Therapeutics RNA immunotherapies manufacturing platform Emeryville, CA Omniome (Acquired) SBB DNA sequencing platform San Diego, CA OneBioMed Instruments for nucleic acid purification/isolation Singapore, SG ONI Desktop super-resolution microscopy Oxford, UK Orbital Therapeutics Platform at the intersection of RNA technology, delivery methods, data science and automation Cambridge, MA Parabilis Medicines New class of drugs aimed at achieving universal druggability for even the most difficult targets Cambridge, MA Paradigm Health Reimagining the clinical trial ecosystem to provide equitable access for all patients New York, NY Paratus Sciences Platform to study bat biology and genomics New York, NY Pheast Therapeutics Immuno-oncology therapies for difficult-to-treat and resistant cancers Palo Alto, CA Pretzel Therapeutics Therapeutics for mitochondrial diseases Waltham, MA Prime Medicine Advanced CRISPR gene editing technology Cambridge, MA | NASDAQ: PRME Protillion Biosciences Rapid platform for antibody discovery and optimization Burlingame, CA Qihan Biotech Next generation cells and organs that can evade immune attacks Hangzhou, China Quanterix Digital diagnostics for molecular detection Lexington, MA | NASDAQ: QTRX Quantum Circuits Developing the first practical quantum computers New Haven, CT Rapport Therapeutics Precision medicines for neurological disorders. Boston, MA | NASDAQ: RAPP Reactive Biosciences Medicines harnessing the unique properties of boron Durham, NC Receptos (Acquired) Targeted drug discovery platform Summit, NJ & CA | NASDAQ: RCPT Recuro Health Digital health platform Dallas, TX Remix Therapeutics Therapeutics to reprogram RNA processing Watertown, MA RIPPL Care Mental healthcare for seniors with dementia and neurocognitive conditions Seattle, WA ROME Therapeutics Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases Cambridge, MA Sana Biotechnology Creating and delivering engineered cells as medicine Seattle, WA | NASDAQ: SANA Scale Biosciences Single-cell sequencing and analysis for research and clinical applications San Diego, CA Scholar Rock Niche activator therapeutics Cambridge, MA | NASDAQ: SRRK SciNeuro Pharmaceuticals Neurotherapeutics to improve China-based patient care Shanghai, China Seaport Therapeutics Neuropsychiatric medicines Seaport Boston, MA Semma Therapeutics (Acquired) Diabetes therapeutics Cambridge, MA Singleron Biotechnologies Massive single-cell processing equipment, software ancd libraries Nanjing, China Singular Genomics Systems Genomic analysis instrumentation San Diego, CA | NASDAQ: OMIC Sironax Therapeutics for inflammatory and nero degenerative diseases Beijing, China Skylark Bio Breakthrough gene therapies to treat hearing loss and sensory impairments Cambridge, MA Slingshot Biosciences On-demand synthetic cell platform Emeryville, CA Sonoma Biotherapeutics T cell therapies for autoimmune and degenerative diseases San Francisco, CA / Seattle, WA SonoThera Ultrasound-directed non-viral gene delivery approach South San Francisco, CA SunBird Bio Blood-based diagnostics for the detection of neurodegenerative diseases Singapore Synchron Brain-computer interface system to restore motor and communication capabilities for paralyzed patients Brooklyn, NY Tenvie Therapeutics for inflammation, metabolic dysfunction and lysosomal function South San Francisco, CA Transcenta Holding Fully integrated antibody-based biotherapeutics company Suzhou, China & Boston, MA | HKEX: 6628 Treeline Biosciences Difficult-to-drug molecular targets in oncology Stamford, CT Trotana Therapeutics Medicines targeting RNA binding proteins San Diego, CA Twist Bioscience Synthetic DNA manufacturing San Francisco, CA | NASDAQ: TWST Unity Biotechnology Therapeutics for age-related diseases & conditions San Francisco, CA | NASDAQ: UBX VBI Vaccines Vaccine therapeutics Cambridge, MA & Quebec, Canada | NASDAQ: VBIV Verve Therapeutics Gene editing therapies to permanently reduce cardiovascular disease Cambridge, MA | NASDAQ: VERV Vesalius Therapeutics AI/ML drug discovery platform for common illnesses Cambridge, MA Vilya Synthetic protein science platform for artificial molecule design Seattle, WA Vir Biotechnology Perpetual vaccine platform San Francisco, CA | NASDAQ: VIR Vividion Therapeutics (Acquired) Protein-based therapeutics San Francisco, CA Vizgen Gene profiling instrumentation and data analysis Cambridge, MA Volastra Therapeutics Cancer genomics and precision medicines New York, NY Walden Biosciences Precision renal therapeutics Cambridge, MA Xaira Therapeutics AI for drug discovery San Francisco, CA Download a list of ARCH’s historical investments COMPANY * About * Portfolio * Initiatives + Strategic Partnerships * Team * News * Contact LOCATIONS * Chicago, IL * Seattle, WA ©2025 Arch Venture Partners Terms of Use Privacy Policy CONNECT | Toggle navigation * About * Portfolio * Initiatives + Strategic Partnerships * Team * News * Contact Our Portfolio We build disruptive companies. Meet them. Read what our entrepeneurs are saying about ARCH. “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.” — David Schenkein, MD, Former CEO Location: Cambridge, MA Date of Founding: Arch Partners: Read More “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges. Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.” — Ryan Watts, Ph.D., CEO Location: San Francisco, CA Date of Founding: Arch Partners: Read More “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals. I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.” — Bill Rastetter, Ph.D., Former Chairman Location: Menlo Park, CA Date of Founding: Sample Date Arch Partners: Read More “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor. In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company. ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.” — Jay Flatley, former Executive Chairman Location: Santa Clara, CA Date of Founding: Sample Date Arch Partners: Read More “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment. ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.” — Hans Bishop, Former CEO Location: Seattle, WA Date of Founding: Arch Partners: Read More “ARCH has been much more of a partner than an investor. ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.” — Emily LeProust, Ph.D., CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Read More “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scangos, Ph.D., Former CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Read More “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress. ARCH is unique in its ability to see the waves before they start to form. They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.” — David Schenkein, MD, Former CEO Location: Cambridge, MA Date of Founding: Arch Partners: “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges. Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.” — Ryan Watts, Ph.D., CEO Location: San Francisco, CA Date of Founding: Arch Partners: “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals. I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.” — Bill Rastetter, Ph.D., Former Chairman Location: Menlo Park, CA Date of Founding: Sample Date Arch Partners: “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor. In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company. ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.” — Jay Flatley, former Executive Chairman Location: Santa Clara, CA Date of Founding: Sample Date Arch Partners: “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment. ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.” — Hans Bishop, Former CEO Location: Seattle, WA Date of Founding: Arch Partners: “ARCH has been much more of a partner than an investor. ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.” — Emily LeProust, Ph.D., CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice. More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies. Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.” — George Scangos, Ph.D., Former CEO Location: San Francisco, CA Date of Founding: Sample Date Arch Partners: Disruptive Companies from Great Science ARCH Portfolio Companies 908 Devices Point-of-need chemical and biomolecular analysis devices Boston, MA | NASDAQ: MASS Accompany Health Correcting disparities in home health care for marginalized communities. Bethesda, MD Aera Therapeutics Protein nanoparticle delivery platform to deliver genetic payloads into multiple organs for better response and fewer reactions. Cambridge, MA Agios Pharmaceuticals Gene-targeted cancer therapeutics Cambridge, MA | NASDAQ: AGIO AIRNA RNA editing technology harnessing endogenous enzymes to prevent off-target edits. Akamis Bio Systemic immune oncology therapies Abingdon, UK Aledade Accountable care organizations Bethesda, MD Alnylam Pharmaceuticals RNAi therapeutics Cambridge, MA | NASDAQ: ALNY Altos Labs Cellular resilience and rejuvenation San Diego, CA Arbor Biotechnologies Protein Discovery Platform for Therapeutics Cambridge, MA Areteia Therapeutics The first oral drug to treat eosinophilic asthma. CHAPEL HILL, NC Arsenal Biosciences Programmable cell cancer therapies South San Francisco, CA Aspen Neuroscience Regenerative medicine focused on Parkinson’s Disease San Diego, CA Autobahn Therapeutics Thyromimetics drug discovery San Diego, CA Basking Biosciences Reversible thrombolytic therapy for acute ischemic stroke Columbus, OH BE Biopharma New class of engineered B cell medicines. Cambridge, MA Beam Therapeutics CRISPR base-editing platform Cambridge, MA | NASDAQ: BEAM Bit Bio Precise reprogramming of stem cells into any desired cell type Cambridge, UK Bitterroot Bio Cardiovascular disease therapies Palo Alto, CA Boundless Bio Therapeutics based on ecDNA discoveries San Diego, CA | NASDAQ: BOLD Brii Biosciences Transforming China's public health Shanghai, China & San Francisco, CA | HKEX: 2137 Carrick Therapeutics Cancer therapeutics Boston, MA City Therapeutics Next generation siRNA medicines Cambridge, MA CStone Pharmaceuticals China-based cancer therapeutics Suzhou, China | HKEX: 2616 Curie Bio Helping biotech company founders launch successful therapeutics firms Boston, MA Cytrellis Biosystems Aesthetic medicine Woburn, MA Denali Therapeutics Neurodegenerative therapeutics San Francisco, CA | NASDAQ: DNLI Dewpoint Therapeutics Translating biomolecular condensate into therapeutics Boston, MA Dispatch Biotherapeutics Immunotherapies to reimagine cancer therapy Philadelphia, PA eGenesis Gene-editing for organ transplantation Cambridge, MA Elephas Biosciences Cancer diagnostics to accurately predict clinical outcomes and accelerate drug development Madison, WI Encoded Therapeutics Precision gene therapies South San Francisco, CA Encodia Protein Analysis Platform San Diego, CA Enumerix Precision DNA counting platform Palo Alto, CA EQRx (Acquired) Re-engineering drug development and pricing models Cambridge, MA | NASDAQ: EQRX Erasca Erasing cancer with AI drug discovery platform San Diego, CA | NASDAQ: ERAS Faraday Pharmaceuticals Ischemic trauma therapies Seattle, WA Gate Bioscience Small molecule drugs against disease-causing proteins Brisbane, CA Generate Biomedicines Multi-disciplinary platform for developing protein therapeutics Cambridge, MA Gossamer Bio Therapeutics in immunology, inflammation, and oncology San Diego, CA | NASDAQ: GOSS Grail (Acquired) Detect cancer early, when it can be cured. Menlo Park, CA hC Bioscience tRNA-based therapeutics for cancer and rare disease Boston, MA HiberCell Therapeutics to prevent cancer relapse and metastasis New York, NY Homeward Health Delivering healthcare to rural communities using a hybrid model of virtual and in-person services San Francisco, CA Hua Medicine Asia-based pharmaceutical development Shanghai, China | HKEX: 2552 Human Immunology Biosciences (Acquired) Precision immunology therapies San Francisco, CA Illumina Diagnostics screening platform Santa Clara, CA | NASDAQ: ILMN Inograft Biotherapeutics Organ and stem cell transplant immune suppression therapies Palo Alto, CA Insitro Machine learning for drug discovery South San Francisco, CA Jaguar Gene Therapy Gene therapies for severe genetic diseases Lake Forest, IL Juno Therapeutics (Acquired) Cancer immunotherapies Seattle, WA | NASDAQ: JUNO JUST Biotherapeutics (Acquired) Therapeutics development & manufacturing Seattle, WA JW Therapeutics China-based cancer therapeutics Shanghai, China | HKEX: 2126 Kardigan Curative therapies for cardiovascular disease South San Francisco, CA Karuna Therapeutics (Acquired) Therapeutics for cognitive impairment Boston, MA | NASDAQ: KRTX Kisbee Therapeutics Neurodegenerative disease therapies based on lipid biology Watertown, MA KSQ Therapeutics Matching Genomic Function to Diseases Cambridge, MA Kura Oncology Cancer therapeutics San Diego, CA | NASDAQ: KURA Kythera Biopharmaceuticals (Acquired) Aesthetic medicine Parsippany, NJ & CA | NASDAQ: KYTH LifeMine Therapeutics Biosynthetic therapeutics Cambridge, MA Lifordi Immunotherapeutics Leveraging anti-drug conjugates to develop treatments for autoimmune and inflammatory disorders Boston, MA Lightcast Discovery Microfluidic platform for complex and single cell analysis Cambridge, UK Lilac Therapeutics Small molecule therapies to treat kidney stones Richmond, CA Lyell Immunopharma Curative cell-based immunotherapeutics for cancer San Francisco, CA & Seattle, WA | NASDAQ: LYEL Magnet Biomedicine Discovery platform for molecular glues that exhibit therapeutic activity Cambridge, MA Matter Neuroscience App pairing personal experience and neuroscience to build better lives Maze Therapeutics Targeting genetic modifiers that can protect against disease San Francisco, CA | NASDAQ: MAZE Metsera Metabolic disease therapeutics Boston, MA | NASDAQ: MTSR Mirador Therapeutics Precision medicines for immunology and inflammation San Diego, CA Moleculent AB Cell-cell communication profiling platform Stockholm, Sweden Moonwalk Biosciences Precision epigenetic editing SOUTH SAN FRANCISCO, CA Mozart Therapeutics Autoimmune disease therapeutics Seattle, WA Myeloid Therapeutics Novel mRNA-immunotherapies to treat cancer Cambridge, MA National Resilience Re-engineering drug manufacturing in the U.S. and abroad La Jolla, CA nChroma Bio In vivo delivery methods for genetic medicines Cambridge, MA Neumora Therapeutics Precision medicines for brain diseases and disorders. Watertown, MA | NASDAQ: NMRA Nutcracker Therapeutics RNA immunotherapies manufacturing platform Emeryville, CA Omniome (Acquired) SBB DNA sequencing platform San Diego, CA OneBioMed Instruments for nucleic acid purification/isolation Singapore, SG ONI Desktop super-resolution microscopy Oxford, UK Orbital Therapeutics Platform at the intersection of RNA technology, delivery methods, data science and automation Cambridge, MA Parabilis Medicines New class of drugs aimed at achieving universal druggability for even the most difficult targets Cambridge, MA Paradigm Health Reimagining the clinical trial ecosystem to provide equitable access for all patients New York, NY Paratus Sciences Platform to study bat biology and genomics New York, NY Pheast Therapeutics Immuno-oncology therapies for difficult-to-treat and resistant cancers Palo Alto, CA Pretzel Therapeutics Therapeutics for mitochondrial diseases Waltham, MA Prime Medicine Advanced CRISPR gene editing technology Cambridge, MA | NASDAQ: PRME Protillion Biosciences Rapid platform for antibody discovery and optimization Burlingame, CA Qihan Biotech Next generation cells and organs that can evade immune attacks Hangzhou, China Quanterix Digital diagnostics for molecular detection Lexington, MA | NASDAQ: QTRX Quantum Circuits Developing the first practical quantum computers New Haven, CT Rapport Therapeutics Precision medicines for neurological disorders. Boston, MA | NASDAQ: RAPP Reactive Biosciences Medicines harnessing the unique properties of boron Durham, NC Receptos (Acquired) Targeted drug discovery platform Summit, NJ & CA | NASDAQ: RCPT Recuro Health Digital health platform Dallas, TX Remix Therapeutics Therapeutics to reprogram RNA processing Watertown, MA RhyGaze AG Cone optogenetics for vision restoration Basel, Switzerland RIPPL Care Mental healthcare for seniors with dementia and neurocognitive conditions Seattle, WA ROME Therapeutics Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases Cambridge, MA Sana Biotechnology Creating and delivering engineered cells as medicine Seattle, WA | NASDAQ: SANA Scale Biosciences Single-cell sequencing and analysis for research and clinical applications San Diego, CA Scholar Rock Niche activator therapeutics Cambridge, MA | NASDAQ: SRRK SciNeuro Pharmaceuticals Neurotherapeutics to improve China-based patient care Shanghai, China Seaport Therapeutics Neuropsychiatric medicines Seaport Boston, MA Semma Therapeutics (Acquired) Diabetes therapeutics Cambridge, MA Singleron Biotechnologies Massive single-cell processing equipment, software ancd libraries Nanjing, China Singular Genomics Systems Genomic analysis instrumentation San Diego, CA | NASDAQ: OMIC Sironax Therapeutics for inflammatory and nero degenerative diseases Beijing, China Skylark Bio Breakthrough gene therapies to treat hearing loss and sensory impairments Cambridge, MA Slingshot Biosciences On-demand synthetic cell platform Emeryville, CA Sonoma Biotherapeutics T cell therapies for autoimmune and degenerative diseases San Francisco, CA / Seattle, WA SonoThera Ultrasound-directed non-viral gene delivery approach South San Francisco, CA SunBird Bio Blood-based diagnostics for the detection of neurodegenerative diseases Singapore Synchron Brain-computer interface system to restore motor and communication capabilities for paralyzed patients Brooklyn, NY Tenvie Therapeutics for inflammation, metabolic dysfunction and lysosomal function South San Francisco, CA Transcenta Holding Fully integrated antibody-based biotherapeutics company Suzhou, China & Boston, MA | HKEX: 6628 Treeline Biosciences Difficult-to-drug molecular targets in oncology Stamford, CT Trotana Therapeutics Medicines targeting RNA binding proteins San Diego, CA Twist Bioscience Synthetic DNA manufacturing San Francisco, CA | NASDAQ: TWST Unity Biotechnology Therapeutics for age-related diseases & conditions San Francisco, CA | NASDAQ: UBX VBI Vaccines Vaccine therapeutics Cambridge, MA & Quebec, Canada | NASDAQ: VBIV Verve Therapeutics Gene editing therapies to permanently reduce cardiovascular disease Cambridge, MA | NASDAQ: VERV Vesalius Therapeutics AI/ML drug discovery platform for common illnesses Cambridge, MA Vilya Synthetic protein science platform for artificial molecule design Seattle, WA Vir Biotechnology Perpetual vaccine platform San Francisco, CA | NASDAQ: VIR Vividion Therapeutics (Acquired) Protein-based therapeutics San Francisco, CA Vizgen Gene profiling instrumentation and data analysis Cambridge, MA Volastra Therapeutics Cancer genomics and precision medicines New York, NY Walden Biosciences Precision renal therapeutics Cambridge, MA Xaira Therapeutics AI for drug discovery San Francisco, CA Download a list of ARCH’s historical investments COMPANY * About * Portfolio * Initiatives + Strategic Partnerships * Team * News * Contact LOCATIONS * Chicago, IL * Seattle, WA ©2025 Arch Venture Partners Terms of Use Privacy Policy CONNECT |
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled